Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

Analysts predict the weight loss drug market to grow between $100 billion and $130 billion by 2030, as per a report.

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Ozempic, the diabetes medication popularly used as an “off-label” weight-loss drug, has helped thousands shed excess pounds.

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity. The dramatic ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO.

Robert F. Kennedy Jr., the nominee to lead the Department of Health and Human Services, made disputed claims before the ...